PD Dr. Agnes Bosch

Medizinische Fakultät Department of Medicine 4 – Nephrology and Hypertension

IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIES (2022) Kannenkeril D, Ott C, Bosch A, Striepe K, Pietschner R, Schiffer M, Schmieder R Conference contribution SEMI-AUTOMATIC MEASUREMENT OF INTIMA-MEDIA THICKNESS OF BRACHIAL ARTERY IN PATIENTS WITH CONGESTIVE HEART FAILURE (2022) Kannenkeril D, Kolwelter J, Pietschner R, Striepe K, Bosch A, Achenbach S, Schmieder R Conference contribution SEMI-AUTOMATIC MEASUREMENT OF INTIMA-MEDIA THICKNESS OF BRACHIAL ARTERY IN PATIENTS WITH CONGESTIVE HEART FAILURE (2022) Kannenkeril D, Kolwelter J, Pietschner R, Striepe K, Bosch A, Achenbach S, Schmieder R Journal article DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILURE (2022) Pietschner R, Kolwelter J, Bosch A, Striepe K, Kannenkeril D, Ott C, Schiffer M, et al. Journal article ANGIOTENSIN PROFILES IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES WITH COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN VERSUS METFORMIN AND INSULIN GLARGINE (2022) Bosch A, Poglitsch M, Kannenkeril D, Ott C, Pietschner R, Striepe K, Schiffer M, Schmieder R Journal article IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIES (2022) Kannenkeril D, Ott C, Bosch A, Striepe K, Pietschner R, Schiffer M, Schmieder R Journal article DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILURE (2022) Pietschner R, Kolwelter J, Bosch A, Striepe K, Kannenkeril D, Ott C, Schiffer M, et al. Conference contribution ANGIOTENSIN PROFILES IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES WITH COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN VERSUS METFORMIN AND INSULIN GLARGINE (2022) Bosch A, Poglitsch M, Kannenkeril D, Ott C, Pietschner R, Striepe K, Schiffer M, Schmieder R Conference contribution Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers (2022) Geßner A, Gemeinhardt A, Bosch A, Kannenkeril D, Staerk C, Mayr A, Fromm M, et al. Journal article The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial (2022) Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, et al. Journal article